The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict DexCom's revenue will improve 3.2% and EPS will remain in the red.
The average estimate for revenue is $22.1 million. On the bottom line, the average EPS estimate is -$0.20.
Last quarter, DexCom reported revenue of $20.1 million. GAAP reported sales were 42% higher than the prior-year quarter's $14.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.19. GAAP EPS were -$0.21 for Q1 versus -$0.19 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 46.7%, 1,060 basis points better than the prior-year quarter. Operating margin was -76.6%, 710 basis points better than the prior-year quarter. Net margin was -70.0%, 1,360 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $94.0 million. The average EPS estimate is -$0.71.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 76 members out of 173 rating the stock outperform, and 97 members rating it underperform. Among 62 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give DexCom a green thumbs-up, and 43 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DexCom is outperform, with an average price target of $12.54.
Over the decades, small-cap stocks like DexCom have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add DexCom to My Watchlist.